|Table of Contents|

Research progress on the occurrence and development of Lynch syndrome

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 06
Page:
1102-1108
Research Field:
Publishing date:

Info

Title:
Research progress on the occurrence and development of Lynch syndrome
Author(s):
XIE Tianci1; 2; XU Xiangshang2
1.Tongji Medical College of Huazhong University of Science and Technology,Hubei Wuhan 430030,China；2.Department of Gastrointestinal Surgery,Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology,Hubei Wuhan 430030，China.
Keywords:
Lynch syndrome; colorectal cancer; hereditary cancer syndromes; mismatch repair gene
PACS:
R735.3
DOI:
10.3969/j.issn.1672-4992.2022.06.032
Abstract:
Lynch syndrome is currently recognized as the most common hereditary colorectal cancer syndrome,which is characterized by the predisposition to a series of cancers,mainly colorectal cancer and endometrial cancer.The carcinogenic tendency of Lynch syndrome stems from changes in the gene structure of a set of mismatch repair proteins.The inactivated mismatch repair protein causes high instability in the microsatellite region of the genome.Over time,the accumulation of mutations in microsatellites and other parts of the genome can affect the number or activity of proteins with important functions in cells,thereby stimulating tumorigenesis.In addition,compared with sporadic cancers,Lynch syndrome-associated cancers have different pathological and clinical characteristics,and the treatment and management of related cancers are also different from those of sporadic cancers.Therefore,the identification of Lynch syndrome diagnosis is very important.With the rapid development of molecular biology in recent years and people's exploration of Lynch syndrome for more than a century,Lynch syndrome has attracted more and more attention.In this review,we summarize the pathogenesis,clinical characteristics,diagnosis,prevention and treatment of Lynch syndrome.

References:

［1］BARNETSON RA,TENESA A,FARRINGTON SM,et al.Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer ［J］.N Engl J Med,2006,354(26):2751-2763.
［2］HAMPEL H,FRANKEL WL,MARTIN E,et al.Screening for the Lynch syndrome(Hereditary nonpolyposis colorectal cancer) ［J］.N Engl J Med,2005,352(18):1851-1860.
［3］NAGY R,SWEET K,ENG C.Highly penetrant hereditary cancer syndromes ［J］.Oncogene,2004,23(38):6445-6470.
［4］CHINTALACHERUVU LM,SHAW T,BUDDAM A,et al.Major hereditary gastrointestinal cancer syndromes:a narrative review ［J］.Journal of Gastrointestinal and Liver Diseases,2017,26(2):157-163.
［5］ENGEL C,LOEFFLER M,STEINKE V,et al.Risks of less common cancers in proven mutation carriers with lynch syndrome ［J］.J Clin Oncol,2012,30(35):4409-4415.
［6］WIN AK,JENKINS MA,DOWTY JG,et al.Prevalence and penetrance of major genes and polygenes for colorectal cancer ［J］.Cancer Epidemiology Biomarkers & Prevention,2017,26(3):404-412.
［7］KOESSLER T,OESTERGAARD MZ,SONG H,et al.Common variants in mismatch repair genes and risk of colorectal cancer ［J］.Gut,2008,57(8):1097-1101.
［8］COX VL,BAMASHMOS AAS,FOO WC,et al.Lynch syndrome:genomics update and imaging review ［J］.Radiographics,2018,38(2):483-499.
［9］HSIEH P,YAMANE K.DNA mismatch repair:Molecular mechanism,cancer,and ageing ［J］.Mech Ageing Dev,2008,129(7-8):391-407.
［10］KUNKEL TA,ERIE DA.DNA mismatch repair ［J］.Annu Rev Biochem,2005,74：681-710.
［11］MOLLER P,SEPPALA T,BERNSTEIN I,et al.Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance:first report from the prospective Lynch syndrome database ［J］.Gut,2017,66(3):464-472.
［12］MENAHEM B,ALVES A,REGIMBEAU JM,et al.Lynch syndrome:Current management in 2019［J］.J Visc Surg,2019,156(6):507-514.
［13］JENKINS MA,HAYASHI S,O' SHEA AM,et al.Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability:A population-based study ［J］.Gastroenterology,2007,133(1):48-56.
［14］NAGTEGAAL ID,ODZE RD,KLIMSTRA D,et al.The 2019 WHO classification of tumours of the digestive system ［J］.Histopathology,2020,76(2):182-188.
［15］MUZNY DM,BAINBRIDGE MN,CHANG K,et al.Comprehensive molecular characterization of human colon and rectal cancer ［J］.Nature,2012,487(7407):330-337.
［16］SCHWITALLE Y,KLOOR M,EIERMANN S,et al.Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers ［J］.Gastroenterology,2008,134(4):988-997.
［17］GIARDIELLO FM,ALLEN JI,AXILBUND JE,et al.Guidelines on genetic evaluation and management of lynch syndrome:a consensus statement by the us multi-society task force on colorectal cancere ［J］.American Journal of Gastroenterology,2014,109(8):1159-1179.
［18］LYNCH HT,DE LA CHAPELLE A.Genomic medicine-hereditary colorectal cancer ［J］.N Engl J Med,2003,348(10):919-932.
［19］LYNCH HT,SMYRK TC,WATSON P,et al.Genetics,natural history,tumor spectrum,and pathology of hereditary nonpolyposis colorectal cancer:an updated review ［J］.Gastroenterology,1993,104(5):1535-1549.
［20］LENGAUER C,KINZLER KW,VOGELSTEIN B.Genetic instabilities in human cancers ［J］.Nature,1998,396(6712):643-649.
［21］PARKER WM,HENNIG K,BURTON-CHASE AM.For women,lynch syndrome is about more than colon cancer ［J］.Cancer Prev Res,2019,12(12):831-835.
［22］OBERMAIR A,YOULDEN DR,YOUNG JP,et al.Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma ［J］.International Journal of Cancer,2010,127(11):2678-2784.
［23］BONADONA V,BONAITI B,OLSCHWANG S,et al.Cancer risks associated with germline mutations in MLH1,MSH2,and MSH6 Genes in lynch syndrome ［J］.JAMA-J Am Med Assoc,2011,305(22):2304-2310.
［24］BOGANI G,TIBILETTI MG,RICCI MT,et al.Lynch syndrome-related non-endometrioid endometrial cancer:analysis of outcomes ［J］.Int J Gynecol Cancer,2020,30(1):56-61.
［25］IONOV Y,PEINADO MA,MALKHOSYAN S,et al.Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis ［J］.Nature,1993,363(6429):558-561.
［26］DENG GR,BELL I,CRAWLEY S,et al.BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1,but not in hereditary nonpolyposis colorectal cancer ［J］.Clinical Cancer Research,2004,10(1):191-195.
［27］SINGH S,RESNICK KE.Lynch syndrome and endometrial cancer ［J］.Southern Medical Journal,2017,110(4):265-269.
［28］VASEN HF,MECKLIN JP,KHAN PM,et al.The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer(ICG-HNPCC) ［J］.Diseases of the Colon and Rectum,1991,34(5):424-425.
［29］VASEN HFA,WATSON P,MECKLIN JP,et al.New clinical criteria for hereditary nonpolyposis colorectal cancer(HNPCC,Lynch syndrome) proposed by the International Collaborative Group n HNPCC ［J］.Gastroenterology,1999,116(6):1453-1456.
［30］UMAR A,BOLAND CR,TERDIMAN JP,et al.Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer(Lynch syndrome) and microsatellite instability ［J］.J Natl Cancer Inst,2004,96(4):261-268.
［31］GREEN RC,PARFREY PS,WOODS MO,et al.Prediction of lynch syndrome in consecutive patients with colorectal cancer ［J］.J Natl Cancer Inst,2009,101(5):331-340.
［32］CHEN S,WANG W,LEE S,et al.Prediction of germline mutations and cancer risk in the Lynch syndrome ［J］.JAMA-J Am Med Assoc,2006,296(12):1479-1487.
［33］KASTRINOS F,STEYERBERG EW,MERCADO R,et al.The PREMM1,2,6 model predicts risk of MLH1,MSH2,and MSH6 germline mutations based on cancer history ［J］.Gastroenterology,2011,140(1):73.
［34］BILLER LH,SYNGAL S,YURGELUN MB.Recent advances in Lynch syndrome ［J］.Familial Cancer,2019,18(2):211-219.
［35］JARVINEN HJ,RENKONEN-SINISALO L,AKTAN-COLLAN K,et al.Ten years after mutation testing for lynch syndrome:cancer incidence and outcome in mutation-positive and mutation-negative family members ［J］.J Clin Oncol,2009,27(28):4793-4797.
［36］SYNGAL S,WEEKS JC,SCHRAG D,et al.Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations ［J］.Annals of Internal Medicine,1998,129(10):787.
［37］CHURCH JM.Controversies in the surgery of patients with familial adenomatous polyposis and Lynch syndrome ［J］.Familial Cancer,2016,15(3):447-451.
［38］HAANSTRA JF,CAPPEL WHDVTN,GOPIE JP,et al.Quality of life after surgery for colon cancer in patients with lynch syndrome:partial versus subtotal colectomy［J］.Diseases of the Colon & Rectum,2012,55(6):653-659.
［39］CAPPEL W,BUSKENS E,VAN DUIJVENDIJK P,et al.Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect ［J］.Gut,2003,52(12):1752-1755.
［40］CARETHERS JM,SMITH EJ,BEHLING CA,et al.Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer ［J］.Gastroenterology,2004,126(2):394-401.
［41］TOUGERON D,MOUILLET G,TROUILLOUD I,et al.Efficacy of adjuvant chemotherapy in colon cancer with microsatellite instability:a large multicenter AGEO study ［J］.JNCI-Journal of the National Cancer Institute,2016,108(7):10.1093.
［42］BERTAGNOLLI MM,NIEDZWIECKI D,COMPTON CC,et al.Microsatellite instability predicts improved response to adjuvant therapy with irinotecan,fluorouracil,and leucovorin in stage III colon cancer:cancer and leukemia group B protocol 89803 ［J］.J Clin Oncol,2009,27(11):1814-1821.
［43］MARTIN SA,MCCABE N,MULLARKEY M,et al.DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1 ［J］.Cancer Cell,2010,17(3):235-248.
［44］ZAANAN A,SHI Q,TAIEB J,et al.Role of deficient DNA mismatch repair status in patients with stage III colon cancer treated with FOLFOX adjuvant chemotherapy a pooled analysis from 2 randomized clinical trials ［J］.Jama Oncology,2018,4(3):379-383.
［45］ANDRE T,DE GRAMONT A,VERNEREY D,et al.Adjuvant fluorouracil,leucovorin,and oxaliplatin in stage II to III colon cancer:updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study ［J］.J Clin Oncol,2015,33(35):4176.
［46］BURN J,GERDES AM,MACRAE F,et al.Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer:an analysis from the CAPP2 randomised controlled trial ［J］.Lancet,2011,378(9809):2081-2087.
［47］MOVAHEDI M,BISHOP DT,MACRAE F,et al.Obesity,aspirin,and risk of colorectal cancer in carriers of hereditary colorectal cancer:a prospective investigation in the CAPP2 study ［J］.J Clin Oncol,2015,33(31):3591.
［48］OUAKRIM DA,DASHTI SG,CHAU R,et al.Aspirin,ibuprofen,and the risk for colorectal cancer in lynch syndrome ［J］.Journal of the National Cancer Institute,2015,107(9):djv170.
［49］CHAU R,DASHTI SG,OUAKRIM DA,et al.Multivitamin,calcium and folic acid supplements and the risk of colorectal cancer in Lynch syndrome ［J］.International Journal of Epidemiology,2016,45(3):940-953.
［50］LU KH,LOOSE DS,YATES MS,et al.Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with lynch syndrome ［J］.Cancer Prev Res,2013,6(8):774-781.
［51］LE DT,URAM JN,WANG H,et al.PD-1 blockade in tumors with mismatch-repair deficiency ［J］.N Engl J Med,2015,372(26):2509-2520.
［52］SPIRA A,DISIS ML,SCHILLER JT,et al.Leveraging premalignant biology for immune-based cancer prevention ［J］.Proceedings of the National Academy of Sciences of the United States of America,2016,113(39):10750-10758.
［53］LYNCH HT,SNYDER CL,SHAW TG,et al.Milestones of Lynch syndrome:1895-2015［J］.Nat Rev Cancer,2015,15(3):181-194.

Memo

Memo:
湖北陈孝平科技发展基金会青年科学专项基金（编号：CXPJJH121003-2104）；2021年华中科技大学同济医学院附属同济医院归国留学人员启动基金(编号：2021HGRY012)
Last Update: 1900-01-01